Felix Sheinerman is a seasoned expert in drug discovery innovation with over 20 years of experience in big pharma and biotechnology. Currently, as the Head of Drug Development Programs at Bioada, they lead initiatives in drug discovery and repurposing. Previously, at the Trudeau Institute, they spearheaded the development of an innovative chemogenomic platform for identifying novel anti-infective molecules. They co-founded nPharmakon LLC, where they pioneered drug retargeting strategies and advanced a first-in-class treatment for hyperpigmentation disorders. Felix obtained a PhD in Molecular and Cellular Structure and Chemistry from The Scripps Research Institute and completed postdoctoral training at Columbia University/Howard Hughes Medical Institute.
This person is not in the org chart
This person is not in any teams
This person is not in any offices